[1] CORTESE I, REICH DS, NATH A.Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease[J]. Nat Rev Neurol, 2021,17(1):37-51. [2] CINQUE P, KORALNIK IJ, GEREVINI S, et al.Progressive multifocal leukoencephalopathy in HIV-1 infection[J]. Lancet Infect Dis, 2009,9(10):625-636. [3] KIM J, KIM C, LEE JA, et al.Long-term prognosis and overall mortality in patients with progressive multifocal leukoencephalopathy[J]. Sci Rep, 2023,13(1):14291. [4] 钱娟, 黄锐, 曹齐, 等. mNGS技术诊断11例人类免疫缺陷病毒相关进行性多灶性白质脑病及其临床特征[J]. 中国神经精神疾病杂志,2022,48(11):657-663. [5] 于芳芳, 张德发, 黄晓婕, 等. 艾滋病合并中枢神经系统疾病48例临床分析[J]. 山东医药, 2021, 61(11):81-84. [6] 中华医学会神经病学分会感染性疾病与脑脊液细胞学学组. 中枢神经系统感染性疾病的脑脊液宏基因组学第二代测序应用专家共识[J]. 中华神经科杂志, 2021, 54(12):1234-1240. [7] 任美吉, 李莉, 赵晶, 等. 艾滋病合并进行性多灶性脑白质病的MRI表现[J/CD]. 新发传染病电子杂志, 2023, 8(2): 23-27. [8] 张仁芳,齐唐凯,陈军, 等. 脑脊液第二代测序技术诊断10例艾滋病相关进行性多灶性白质脑病的临床分析[J]. 中华传染病杂志,2020,38(12):786-791. [9] 陈兴泳,赖静兰,陈雅红, 等. 人免疫缺陷病毒相关进行性多灶性白质脑病1例临床、影像和病理特征[J]. 中国神经精神疾病杂志,2021,47(1):47-49. [10] TAN CS, KORALNIK IJ.Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesis[J]. Lancet Neurol, 2010,9(4):425-437. [11] BERNARD-VALNET R, KORALNIK IJ, DU PASQUIER R.Advances in Treatment of Progressive Multifocal Leukoencephalopathy[J]. Ann Neurol, 2021, 90(6):865-873. [12] JELCIC I, JELCIC I, FAIGLE W, et al.Immunology of progressive multifocal leukoencephalopathy[J]. J Neurovirol, 2015, 21(6):614-622. [13] 中华医学会感染病学分会艾滋病丙型肝炎学组,中国疾病预防控制中心.中国艾滋病诊疗指南(2018版)[J/CD].新发传染病电子杂志,2019,4(2):65-84. [14] SU B, YAO C, ZHAO QX, et al.Long-acting HIV fusion inhibitor albuvirtide combined with ritonavir-boosted lopinavir for HIV-1-infected patients after failing the first-line antiretroviral therapy: 48-week randomized, controlled, phase 3 non-inferiority TALENT study[J]. J Infect, 2022,85(3):334-363. [15] SU B, YAO C, ZHAO QX, et al.Efficacy and safety of the long-acting fusion inhibitor albuvirtide in antiretroviral-experienced adults with human immunodeficiency virus-1: interim analysis of the randomized, controlled, phase 3, non-inferiority TALENT study[J]. Chin Med J (Engl), 2020,133(24):2919-2927. |